GEN Exclusives

More »

GEN News Highlights

Back to Item »

GlycoRegImmune Partners with RxMD to Progress NK T Cell-Targeting Drugs

Startup biotech is developing type I NKT inhibitors and type II NKT modulators against inflammatory and autoimmune diseases.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?